Syndrome News and Research

RSS

New SARS-CoV-2 B.1.526 variant emerges in New York

New York has the first case of a new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant called B.1.526, picked up by genomic surveillance research from Columbia University. The findings come after reports of other variants have been reported worldwide — B.1.1.7 in the United Kingdom, B.1.351 in South Africa, and P.1/P.2 in Brazil.

28 Feb 2021

Free-ranging minks exhibit high titers of SARS-CoV-2 antibodies in Utah

Researchers at the U.S. Centers for Disease Control and Prevention (CDC) report outbreaks of coronavirus disease (COVID-19) on mink farms in Utah, United States. They surveyed around farms for evidence of exposure and found high SARS-CoV-2 titers, suggesting a possible viral transmission pathway to native wildlife.

28 Feb 2021

Time to implement measures preventing future viral zoonoses

Now, researchers at the University of Silesia in Katowice and the Poznan University of Medical Sciences in Poland recommend measures to prevent future zoonotic outbreaks. They emphasized the importance of viral surveillance and research on new viral strains as primary strategies to combat these infections.

28 Feb 2021

SARS-CoV-2 modulates host cell central carbon metabolism for reproduction

A team of scientists from Sweden and India has recently characterized the host cell metabolic alterations associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Their findings reveal that SARS-CoV-2 modulates the host cell's central carbon metabolism to facilitate replication and infection propagation.

28 Feb 2021

New method to enhance images of the SARS-CoV-2 virus

Researchers report a method of removing noise from high-resolution transmission electron microscopy images using probabilistic generative models.

28 Feb 2021

New study assesses COVID-19 risk among UK healthcare workers

Researchers in the UK have reported the protocol for a longitudinal study investigating the risk of adverse physical and mental health outcomes related to coronavirus disease 2019 (COVID-19) among healthcare workers from different ethnic groups.

28 Feb 2021

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

A new study by researchers in the U.S. further supports the hypothesis that the unregulated release of inflammatory cytokines is responsible for the local and systemic inflammation that is associated with multi-organ damage and death in severe COVID-19.

26 Feb 2021

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A new study deals with the clinical and virological effects of circulating SARS-CoV-2 variants, especially as they affect vaccine efficacy.

26 Feb 2021

A missing protein explains the appearance of tumor cells in people with Mulibrey syndrome

Researchers from the Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), in collaboration with the Swiss Institute for Experimental Cancer Research (ISREC) have studied the mechanisms behind the higher tendency of people with Mulibrey syndrome to develop tumors.

26 Feb 2021

Repurposed drugs show antiviral SARS-CoV-2 E channel blocking activity, finds study

A new study by researchers at The Hebrew University of Jerusalem in Israel reports the discovery of a promising group of E channel inhibitors with significant antiviral activity. This could be developed into new treatment agents for this often-deadly virus.

26 Feb 2021

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

A new study by a team of researchers in the UK and US describes the use of a computational tool that generates all possible single amino acid substitutions in SARS-CoV-2 and predicts their effects.

26 Feb 2021

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

A new study by researchers at Brookhaven National Laboratory and Stony Brook University in the U.S. describes the key interaction between the viral envelope (E) protein and the human cell junction protein, PALS1. The latter is necessary to establish and maintain cell polarity and tight junctions between cells.

26 Feb 2021

Learning to live again: A Lazarus tale from the Covid front lines

The twinkle in his eyes, the delight in his smile, the joyous way he moved his disease-withered frame. They all proclaimed a single, resounding message: Grateful to be alive!

26 Feb 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

What is the impact of demographics and air quality on COVID-19 mortality?

A new piece of research was conducted using a wide range of variables related to demographic and environmental factors in New York State (NYS), USA. NYS consists of urban and ethnically diverse counties, some of which are population-dense while others are population-sparse.

26 Feb 2021

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Researchers evaluated the immune response in a cohort of 1,089 healthcare workers who received the Pfizer-BioNTech vaccine in Southern California.

26 Feb 2021

Mandatory public health measures to combat COVID-19 are more effective, says study

In a new study, researchers at Lundberg Health Advocates and the Johns Hopkins Bloomberg School of Public Health in the U.S. compared mandatory and voluntary implementations of shelter-in-place policies. They assessed their respective bearings on COVID-19 mortality, equity, and economic outcomes.

26 Feb 2021

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

The first instance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Austria was observed in the Ski resort Ischgl in early March 2020. Later, the virus spread across Austria and other countries in Northern Europe.

25 Feb 2021

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

A team of researchers from Spain and Canada recently characterized the antibody kinetics and neutralization capacity at 4 cross-sectional surveys between March and October 2020 and determined the seroprevalence in the same cohort of healthcare workers.

25 Feb 2021

Microbes could predict fatal outcomes in ventilated COVID-19 patients

The study "Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome" is available as a preprint on the medRxiv* server, while the article undergoes peer review.

25 Feb 2021

Syndrome News and Research

New SARS-CoV-2 B.1.526 variant emerges in New York

Free-ranging minks exhibit high titers of SARS-CoV-2 antibodies in Utah

Time to implement measures preventing future viral zoonoses

SARS-CoV-2 modulates host cell central carbon metabolism for reproduction

New method to enhance images of the SARS-CoV-2 virus

New study assesses COVID-19 risk among UK healthcare workers

NLRP3 inflammasome inhibitors may help treat early COVID-19, says study

South African SARS-CoV-2 variant partly resistant to neutralization by mRNA vaccine, says study

A missing protein explains the appearance of tumor cells in people with Mulibrey syndrome

Repurposed drugs show antiviral SARS-CoV-2 E channel blocking activity, finds study

Researchers develop new tool for predicting the effects of SARS-CoV-2 missense variants

Structure of SARS-CoV-2 envelope protein-epithelial cell junction protein complex explains virulence

Learning to live again: A Lazarus tale from the Covid front lines

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

What is the impact of demographics and air quality on COVID-19 mortality?

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Mandatory public health measures to combat COVID-19 are more effective, says study

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Microbes could predict fatal outcomes in ventilated COVID-19 patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News